Fig. 3From: A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanomaSurvival by demographic variables. a Survival by ECOG performance status, b Survival by metastatic status, c Survival by brain metastases and d Survival by treatment naïve/experiencedBack to article page